Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?

Nature Clinical Practice Oncology volume 3, pages 16–17 (2006)Cite this article

Access through your institution
Buy or subscribe

boxed-textRichardson PG et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487–2498

Background

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hideshima T et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071–3076

    CAS  PubMed  Google Scholar 

  2. Orlowski RZ et al. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20: 4420–4427

    Article  CAS  Google Scholar 

  3. Richardson PG et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609–2617

    Article  CAS  Google Scholar 

  4. Jagannath S et al. (2005) Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials [abstract #6501]. J Clin Oncol 24 (Suppl): 560s

    Google Scholar 

  5. Orlowski RZ et al. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105: 3058–3065

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The author, who is a Leukemia and Lymphoma Society Scholar in Clinical Research, and a Jefferson-Pilot Fellow in Academic Medicine, would also like to acknowledge support from the National Cancer Institute (RO1 CA102278) and the Multiple Myeloma Research Foundation.

The synopsis was written by Alexandra King, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

    Robert Z Orlowski

Authors
  1. Robert Z Orlowski
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Robert Z Orlowski.

Ethics declarations

Competing interests

Speaker's bureau for Millennium Pharmaceuticals, Inc. Consultant for Johnson and Johnson PRDU, and Celgene Corporation.

Supplementary information

Supplementary Table 1

Efficacy of bortezomib or dexamethasone against relapsed and refractory multiple myeloma based on the number of prior therapies

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orlowski, R. Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?. Nat Rev Clin Oncol 3, 16–17 (2006). https://doi.org/10.1038/ncponc0382

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncponc0382

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing